Wegovy Pill Outperforms Foundayo as Medicare Drives Novo's Third Guidance Lift
· techtimes.com · popularity 19/100 · 0 similar stories today · Medicine & Clinical Health (Health & Life Sciences)
Read the original at techtimes.com →
Summary
Wegovy pill sales surged 53% in Q3 2026 to approximately $811 million, beating analyst estimates by 17%, as Medicare's new GLP-1 Bridge pilot program capped monthly costs at $50 for eligible seniors. Novo Nordisk raised its full-year 2026 outlook for a third consecutive time and announced CFO Karsten Munk Knudsen's departure after 27 years, while oral semaglutide's 16.6% weight-loss efficacy continues to outpace rival Foundayo's 12.4% in indirect comparisons.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 7.